Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To demonstrate that the addition of oxaliplatin to 5-Fluorouracil (5-FU) and Leucovorin (LV)
will improve the Progression-Free Survival (PFS). Progression is based on RECIST (Response
Evaluation Criteria In Solid Tumors) criteria or death
Secondary Objective:
To evaluate other measures of tumor responses, safety, quality of life (QoL), and health
utility assessment.